BRIEF-FibroGen's Roxadustat (FG-4592) meets primary endpoints in two phase 3 anemia studies in China
* FibroGen's Roxadustat (FG-4592) meets primary endpoints in two phase 3 anemia studies in China [Source]
Publication Date:Origin: reuters.com
Category: rbssHealthcareNews
Topics: China, studies, anemia, phase, endpoints, primary, meets, (FG-4592), Roxadustat, in two, FibroGen's, BRIEF-FibroGen's
Source: http://feeds.reuters.com/~r/reuters/UShealthcareNews/~3/XBLbkHbwAgE/idUSFWN1FK0AB